EligibleTrials

Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure

Recruiting · NCT04262830 · Observational (researchers observe without assigning treatment) · Lead sponsor: Hari Narayan

View the official record on ClinicalTrials.gov →
Heart Failure

Interventions studied

Accelerometer physical activity monitoringCardiac magnetic resonance imaging (MRI)

What this trial is about

Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. This study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies.

Who can take part

Age range
13 Years to 39 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)

Inclusion criteria

Exclusion criteria

Where it is running

1 location listed across 1 US state.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.